Unilabs’ Patients get faster diagnosis of sepsis through the project SMARTDIAGNOS

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...
Unilabs Sweden is a key player to the EU project "SMARTDIAGNOS- Next Generation sepsis diagnosis technology", which provides rapid diagnostics and better conditions for treatment for patients with blood poisoning.
 
Blood poisoning, known as sepsis, is a potentially fatal immune response of the human body, often caused by bacterial or fungal infection. Early diagnosis is crucial for proper treatment.
 
"Unilabs eagerly looks forward to contributing to this important project", says Helena Enroth, development manager Molecular Unilabs Skövde and adjunct professor at the University of Skövde.
 
Ten partners consisting of companies, institutions and universities, runs the SMARTDIAGNOS- project simultaneously. The 4-years running project has received funding from the EU's "Horizon 2020 Research and Innovation Programme under the grant agreement No. 687 697 ". The project started om February 1, 2016.
 
SMARTDIAGNOS will provide fast and accurate sepsis diagnosis, with the ability to reduce morbidity and mortality by up to 20%. 

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »